Robaxin®-V Injectable — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Robaxin®-V Injectable

Active ingredient

Methocarbamol

Application type

NADA

Sponsor

Kinetic Technologies, LLC

Applications on record

1

First published

November 3, 2016

Adverse event reports

Source: openFDA VeDDRA

686

Reports mentioning this ingredient

August 16, 1996 – March 17, 2026

392

Classified serious

per reporter assessment

74

Lack of expected efficacy

resistance signal

10

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “METHOCARBAMOL”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Solution, Abnormal	38
Vials, Damaged	4
Color, Abnormal	3
Seal, Abnormal	3
Death by euthanasia	3
Missing Cap	3
Vials, Leaking	3
Elevated liver enzymes	2
Ataxia	2
Depression	2
Suspension, Abnormal	2
Loss of consciousness	2
Anaemia NOS	2
Injection site swelling	2
Death	2
Recumbency	2
No sign	1
Skin necrosis	1
TOXICITY	1
Dependent oedema	1

Species affected

Source: openFDA VeDDRA

Dog 589 Cat 39 Horse 6 Human 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient